Novartis Pops — Hammering Rival Travere Therapeutics — On Its Kidney Drug Approval

byiShook Opinion
Apr 3, 2025 - 11:35

Share

Novartis stock popped Thursday — prompting Travere Therapeutics to slide — after winning FDA approval for a kidney disease treatment. The post Novartis Pops — Hammering Rival Travere Therapeutics — On Its Kidney Drug Approval appeared first on Investor's Business Daily.

Novartis stock popped Thursday — prompting Travere Therapeutics to slide — after winning FDA approval for a kidney disease treatment.

The post Novartis Pops — Hammering Rival Travere Therapeutics — On Its Kidney Drug Approval appeared first on Investor's Business Daily.